Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been confirmed by tissue testing to have a type of blood cancer called Non-Hodgkin Lymphoma (NHL) or a specific subtype called Peripheral T-Cell Lymphoma (PTCL), and whose cancer has come back or stopped responding to previous treatment (the exact requirements depend on which part of the trial a person is being considered for — confirm with trial site)
- People whose cancer has been treated with at least one previous round of treatment, with the total number of prior treatments falling within a specific range depending on the trial phase (confirm with trial site)
- People who are able to provide suitable tissue samples for central laboratory testing
- People whose general health and ability to carry out daily activities is rated at a level of 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work)
- People with a life expectancy of at least 3 months before starting treatment in this trial
- People whose bone marrow, liver, and kidneys are functioning well enough to meet the trial's requirements
Who may not be able to join:
- People who have previously been treated with a specific class of drugs called EZH2 or EZH1/2 inhibitors
- People whose cancer has spread to the central nervous system (brain and spinal cord)
- People who have any history of a bone marrow cancer, including a condition called myelodysplastic syndrome (MDS)
- People who have taken certain medications known to strongly affect how the body processes drugs (specifically strong CYP3A4 inducers or inhibitors) within one week before the first dose of the trial treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tongyu Li, MD, Sichuan Cancer Hospital and Research Institute
Phone: 86-20568888
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase Ib: To determine the RP2D of HH2853 in PTCL patients; Phase II: To evaluate the efficacy of HH2853 of R/R PTCL patients who have received at least one prior systemic combination chemotherapy and at least one new drug
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.